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PURPOSE. Thyroid-associated orbitopathy (TO) is an autoimmune-mediated orbital inflamma-
tion that can lead to disfigurement and blindness. Multiple genetic loci have been associated
with Graves’ disease, but the genetic basis for TO is largely unknown. This study aimed to
identify loci associated with TO in individuals with Graves’ disease, using a genome-wide
association scan (GWAS) for the first time to our knowledge in TO.
METHODS. Genome-wide association scan was performed on pooled DNA from an Australian
Caucasian discovery cohort of 265 participants with Graves’ disease and TO (cases) and 147
patients with Graves’ disease without TO (controls). Top-ranked single nucleotide
polymorphisms (SNPs) then were genotyped in individual DNA samples from the discovery
cohort, and two replication cohorts totaling 584 cases and 367 controls.
RESULTS. In the GWAS of pooled DNA samples, several SNPs showed suggestive association
with TO at genome-wide P  106; rs953128 located on chr10q21.1, rs2867161 on
chr7q11.22, rs13360861 on chr5q12.3, rs7636326 on chr3q26.2, rs10266576 on chr 7q11.22,
rs60457622 on chr3q23, and rs6110809 on chr20p12.1. However, the only SNP consistently
associated with TO on individual genotyping in the discovery and replication cohorts was
rs6110809, located within MACROD2 on chromosome 20p12.1. On combined analysis of
discovery and replication cohorts, the minor A allele of rs6110809 was more frequent in TO
than in Graves’ disease controls without TO (P ¼ 4.35 3 105; odds ratio [OR] ¼ 1.77; 95%
confidence interval [CI], 1.35–2.32) after adjusting for age, sex, duration of Graves’ disease,
and smoking.
CONCLUSIONS. In patients with Graves’ disease, a common genetic variant in MACROD2 may
increase susceptibility for thyroid-associated orbitopathy. This association now requires
confirmation in additional independent cohorts.
Keywords: genome-wide association study, genotyping, thyroid-associated orbitopathy
Thyroid-associated orbitopathy (TO) is an autoimmune-mediated orbital inflammation affecting 25% to 50% of
patients with Graves’ disease (GD).1 The overall age-adjusted
incidence rate of TO is 16 cases per 100,000 per year for
females and 2.9 cases per 100,000 population per year for
males. The average age at diagnosis is 44.7 years.2 The onset of
TO occurs mostly within 18 months of diagnosis of GD,3 and
the close temporal relationship suggests the two diseases share
a common autoantigen.
Genetic susceptibility for GD is complex and involves
multiple genetic loci regulating immune system and thyroid-
specific genes. The HLA class II alleles, CTLA4, PTPN22, CD40
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polymorphisms were identified early on by candidate gene
association studies as genetic risk factors for GD, even though
the overall contributions from each of these genetic variants
are modest.4–7 The introduction of high throughput microarray
technology, in combination with large cohorts of cases and
controls, has seen genome-wide association studies (GWAS)
revolutionize the study of the genetics of complex traits, and
has allowed detection of association of common genetic
variants with many diseases.8 The earliest GWAS studies of
autoimmune thyroid disease reported associations with HLA
class I and II regions, and TSHR and FCRL3 genes.9 Subsequent
GWAS studies replicated association of FCRL3, HLA loci, TSHR,
CTLA4, PTPN22, IL2RA, and discovered new susceptibility loci
at SENP1, SLAMF6, RNASET2-FGFR1OP-CCR6, an intergenic
region at 4p14, MMEL1, LPP, BACH2, PRICKLE1, and
ITGAM.10–13
Although genetic risk factors for GD are becoming well
defined, limited progress has been made with TO, largely due
to small sample sizes limiting power to detect modest genetic
effects and failure to replicate genetic findings. Candidate gene
studies, predominantly of genes and polymorphisms associated
with GD or genes involved in immune response and
inflammation, have been investigated for a contribution to
TO. While some studies showed CTLA4, HLA I, and II alleles,
and IL-23R rs10889677 and rs2201841 SNPs were associated
with TO compared to GD controls, other studies have not
supported these associations.14–21 TNF-a alleles were associat-
ed significantly with TO in a Japanese but not in a Polish
study.22,23 The adipogenesis-related gene PPARc Pro12Ala
polymorphism decreased the risk of TO in one study but not
in another, but both studies found the Pro12Ala variant
possibly reduces the severity and activity of TO.24,25 Using
tag single nucleotide polymorphisms (SNP), adipocyte-related
immediate early genes showed increased risk for TO with
genetic variants in CYR61 (rs1378227), ZFP36 (rs1057745,
rs11083522), and SCD (rs1393491) with odds between 1.3 and
1.4 compared to GD, but the findings must be replicated.26
Similarly, using tag SNPs, SNPs in IL-1b did not differ between
TO and non-TO in GD in one study but C allele of rs1143634
increased the risk in TO and GD compared to normal
controls,27 whereas another identified rs1800587 polymor-
phism at IL-1a and rs16944 polymorphism at IL-1b significantly
associated with GD and TO.28 PTPN12 (rs1468682, rs4729535,
and rs17467232), functionally related to PTPN22, was
associated with TO compared to non-TO in GD with odds at
1.4, and 2 of the SNPS (rs1468682 and rs4729535) showed
interactions with TSHR rs2268458 SNP; the findings again
require replication.29 However, TSHR rs2268458 SNPs, previ-
ously found to be associated with GD, were not associated with
TO.18
A pooled GWAS study is a cost-effective screening strategy
for identifying gene variants in multiple diseases. Pooled DNA
strategy has successfully identified known susceptibility loci
CFH, ARMS2/HTRA1 in age-related macular degeneration,
LOXL1 in pseudoexfoliation syndrome, and discovered new a
susceptibility locus HGF in keratoconus.30,31 We aim to use a
GWAS to discover genomic loci associated with TO. We report
the first attempts to our knowledge at using a genome-wide
association scan for discovering genetic variants in TO, and an
association of variants in the MACROD2 gene suggesting it as a
new TO susceptibility locus.
METHODS
The genetic study of TO was approved by human research
ethics committees at multiple recruitment sites; the Royal
Victorian Eye and Ear Hospital, Sunshine and Footscray
Hospitals, the Royal Melbourne Hospital, and the Alfred
Hospital in Melbourne, Victoria, Australia, and Flinders Medical
Centre, and the Royal Adelaide Hospital in Adelaide, South
Australia. The genetic research was conducted in accordance
with the Declaration of Helsinki.
Australian Thyroid-Associated Orbitopathy
Research (ATOR) Cohorts
Definition of Graves’ Disease and TO. Graves’ disease
was defined by the presence of hyperthyroidism based on
thyroid function test, including T3, T4, and TSH, and either
elevated thyrotropin receptor (TSHR) antibodies or diffuse
uptake on technetium-99m pertechnetate thyroid scan. Cases
are defined by the presence of TO clinically and controls by the
absence of TO.
Thyroid-associated orbitopathy was defined by the presence
of symptoms of TO and at least one sign of TO, for example, lid
retraction. Early symptoms of TO were detected using the
Vancouver Orbitopathy Rule symptom questionnaire, includ-
ing red eyes, lids swelling, eye protrusion and stare, and
blurred vision.32 Thyroid-associated orbitopathy status was
examined and classified using the Vision, Inflammation,
Strabismus, and Appearance (VISA) classification.33 Ophthal-
mologic measurements included the following: visual acuity,
pupil response, color vision, inflammatory index score,
extraocular movement, strabismus, lid measurements includ-
ing palpebral aperture, marginal reflex distance, lid retraction,
and Hertel exophthalmometry. The status of TO was deter-
mined by an ophthalmologist.
ATOR Discovery Cohort. Thyroid-associated orbitopathy
cases (n ¼ 265) and GD without TO controls (n ¼ 147) of
European descent were recruited from endocrine and eye
hospital outpatient clinics and private practices of endocrinol-
ogists and ophthalmologists from Victoria and South Australia.
Whole blood samples in EDTA were stored at 48C.
Replication Cohorts. A further 319 TO cases and 220 GD
controls were recruited from Victoria and Western Australia as
replication cohorts. These comprised 231 TO cases and 142
GD controls recruited from Victoria using the same protocol as
the ATOR discovery cohort, and 88 TO cases and 78 GD
controls of European descent recruited from endocrine and
ophthalmology clinics in Western Australia. Thyroid-associated
orbitopathy was defined clinically by the presence of eye
symptoms and signs with severity classified according to the
European group on Graves’ orbitopathy (EUGOGO) recom-
mendations (by coauthor JW)34 or VISA classification (by
coauthor AG).33 DNA samples (50 ng/lL) from venous blood
were used for individual genotyping.
A total of 282 normal controls, consisting of healthy
hospital volunteers and retirement village residents over 50
years of European descent from South Australia, were used for
additional individual genotyping for comparison with the TO
and GD cohorts (with and without TO), respectively. The
normal control cohort was not actively screened for GD, but
no participant reported having this condition.
DNA Pooling for GWAS Study in the Discovery Cohort.
Venous blood aliquots from the discovery cohort were stored at
48C before construction of 2 comparative blood pools (pool
number 1, 154 TO cases versus 102 controls; pool number 2, 116
TO cases versus 40 controls), totaling 270 cases and 142
controls. In between the construction of the blood pools and
individual genotyping, the phenotypes of 5 individuals were
updated (5 from cases to controls); these small numbers do not
materially affect the overall blood pool results. Protease and lysis
buffer were added to 100 lL of thawed whole blood from each
sample, vortexed, and incubated, and then samples were
combined in one tube for each pool. DNA was extracted from
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the pooled blood using the QIA-amp DNA blood maxi kit
(Qiagen, Valencia, CA, USA) according to the manufacturer’s
protocol. For the remaining discovery samples, equimolar DNA
pools were generated in duplicate after stepwise dilutions of
genomic DNA extracted using QIA-amp DNA blood maxi kit to
75 ng/lL as previously described.30,31 The DNA was quantitated
using Fluroskan Ascent (ThermoFisher Scientific, Waltham, MA,
USA) together with double-stranded DNA quantitation assay
using Picogreen reagents. (Invitrogen, Carlsbad, CA, USA). A total
of 451 ng of DNA from each sample was added to the DNA pool.
Pooled Genotyping and Analysis
Genome-wide genotyping was conducted by hybridization to
HumanOmni5-Quad (Illumina, San Diego, CA, USA) beadchip
microarray containing approximately 4.3 million markers, at
QIMR Berghofer Medical Research Institute, according to
standard protocol for case and control pools on two
independent arrays for each pool. Two case pools and two
control pools were generated and assigned into two case–
control pool comparisons. Each pool was replicated 2 to 4
times to reduce measurement error. For the purpose of this
analysis, we retained SNPs with minor allele frequency (MAF)
over 1% from the reference panel of EUR samples in the 1000
Genome Project (excluded 1.8 M SNPs). Thus, the number of
SNPs was reduced to 2.5 million. The output of the raw red and
green bead scores from Illumina Beadstation was used for the
pooled data analysis. The data cleaning and quality control
procedures in array-based pooling have been described
previously.35–37 Briefly, SNPs with more than 10% negative
scores on each array were excluded, as well as the SNPs with
the sum of mean red and green scores lower than 1200 across
each array to ensure calibration was performed on a
precleaned dataset. A normalization/correction factor (corr)
was calculated to make the mean value of the pooling allele
frequency (PAF) 0.5 across all SNPs on each strands of the
array. The PAF then was estimated based on the raw red
intensities and the corrected green intensities for all the SNPs
[PAF ¼ red/(red þ green/corr)].36 Further quality control
included filtering nonautosomal SNPs and any SNPs with a
significant variance difference between cases and controls.
After data cleaning, 2.2 M SNPs were left for association testing
in the ATOR discovery cohort. A linear model was used to test for
allelic association in the two case–control pool comparisons. A
test statistic, which corrects for pooling error, was used to rank
SNPs, with P values based on a v2 distribution with 1 degree of
freedom. The application of the test statistic is based upon
contrasting case and control pools, the effect of unequal
amplification of alleles is minimal as such effects cancel out.35
Specifically, a final set of autosomal SNPs was determined meeting
the following criteria: (1) have sufficient number of probes (i.e.,
over 1/2 of expected number of probes for MAF 1% to 5%, or over
1/3 of expected number of probes for SNPs>5%; and (2) have no
large differences (>0.3) between PAF and reference allele
frequency from EUR samples in the 1000 Genome Project. We
then performed a meta-analysis weighted by inverse variance,
combining results from two case–control pool comparisons. The
top-ranked SNPs in the meta-analysis then were counter checked
for proxies (linkage disequilibrium r2> 0.5 with the index SNPs
in the EUR populations). To be considered a valid result, if proxy
SNPs were available, they also should show evidence of
association. A genome-wide significance threshold of 5 3 108
was set to account for multiple testing.
Validation Genotyping and Analysis
Top-ranked SNPs with P value threshold  13 106 indicative
of association, or corresponding proxy if failed genotyping,
were selected for individual genotyping in the discovery and
replication cohorts, to validate pooled genotyping results as
well as to replicate the associations in independent samples. In
total, 7 SNPs were genotyped on Sequenom iPLEX Gold assay
using Sequenom MassARRAY Analyzer in 2 batches, the ATOR
discovery cohort and Western Australia replication cohort
were genotyped at the Australian Genome Research Facility
(Brisbane, Australia), and the ATOR replication cohort at
GeneWorks Pty Ltd. (Adelaide, Australia). The allelic associa-
tion analysis was performed in PLINK,38 using a v2 test and
performed separately for the ATOR pooled discovery cohort
for validation, the replication cohorts, and for combined
discovery and replication cohorts. The odds ratio (OR) and P
values were adjusted for age of disease onset, duration of GD,
and sex using logistic analysis. Single nucleotide polymor-
phisms with P  1 3 104 were considered validated in
validation genotyping. In the replication cohort, P < 0.05 was
considered associated. In the secondary analysis, we further
adjusted the individual genotyping results for smoking status
(smoker, ex-smoker, and never smoked) in addition to sex, age,
and duration of GD for the discovery, replication, and
combined cohorts, bearing in mind there are missing data
points for smoking in 10.9% of the replication cohorts. Further
individual genotyping for the top ranking SNPS were compared
between TO and normal controls; and between GD and normal
control to differentiate whether the validated SNPs were
associated with TO and GD as a whole or the risk variant is
specific for TO in GD. As smoking status data were not
available from the healthy controls, the genotyping results for
these genotyping analyses were adjusted for sex and age only.
Following individual genotyping in discovery and replica-
tion cohorts revealing rs6110809 in MACROD2 as the locus of
interest, further SNPs residing in MACROD2 with nominal P 
5 3 104 were extracted from pooled GWAS top ranking data.
They were assessed for linkage disequilibrium with rs6110809,
to determine if multiple independent risk alleles were
potentially present within MACROD2. Genotype data limited
to a 100 kb region of MACROD2 capturing all 4 additional SNPs
were downloaded from International Hapmap Project (avail-
able in the public domain at http://hapmap.ncbi.nlm.nih.gov/
cgi-perl/gbrowse/hapmap24_B36/#search). Genotype data
were analyzed in HaploView (Version 1.0, Broad Institute) for
pairwise comparisons of marker SNPs with minor allele
frequency > 0.01.
RESULTS
The age at disease onset, duration of GD, sex, and smoking
status distributions of the three cohorts of participants are
described in Table 1. Thyroid-associated orbitopathy cases
were slightly older compared to GD without TO at diagnosis
and the duration of GD in TO cases was longer. The
proportions of males to females were similar between the
groups and the proportion of smokers was greater in cases
compared to controls for ATOR cohorts. The age and sex
distribution of the normal controls in comparison with TO as a
whole and GD as a whole are shown in Table 2.
Pooled DNA was used to identify genetic variants associated
with TO. None of the top ranked SNPs reached the genome-
wide significance threshold of 5 3 108 (Supplementary Table
S1), nevertheless multiple top ranked SNPs approached
genome-wide significance with P  106 and in particular
with rs2867161 on chr7q11.22 (P ¼ 5.94 3 108) and
rs60457622 on chr3q23 (P ¼ 9.28 3 108) almost reaching
significance (Table 3).
The seven top ranked SNPs from pooled GWAS were
individually genotyped in the ATOR discovery cohort.
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rs6110809 was validated with P < 13 104, the minor allele is
associated with TO risk, showing higher frequency in cases
compared to controls (Table 3). After further adjustment for
smoking, rs6110809 was associated with TO with OR at 2.66
(95% confidence interval [CI], 1.69–4.18; P ¼ 2.45 3 105) in
the discovery cohort.
All 7 SNPs also were assessed in the replication cohorts. The
only SNP consistently associated with TO in replication
cohorts was rs6110809, located within an intron of MACROD2
on chromosome 20p12.1 with an age, duration, sex-adjusted
OR 1.42 (95% CI, 1.04–1.95; P¼0.03); after further adjustment
for smoking, the OR was 1.35 (95% CI, 0.96–1.91; P ¼ 0.08).
Overall, for the combined discovery and replication cohorts,
the MACROD2 rs6110809 was associated with TO compared
to GD controls without TO (OR¼ 1.81; 95% CI, 1.40–2.34; P¼
6.78 3 106; Table 4). After adjusting for age, duration of GD,
sex, and smoking, the minor A allele was more frequent in TO
than in GD without TO with OR 1.77 (95% CI, 1.34–2.32; P¼
4.35 3 105).
Additional individual genotyping analyses were undertaken
to determine if the top ranking SNPs from pooled GWAS in TO
versus non-TO in GD were associated with TO or GD as a
whole or the risk variant was specific to TO in GD. We found
that none of the seven top ranking SNPS was associated with
TO compared to normal individuals or GD compared to normal
individuals (Supplementary Table S2). Hence, SNP at MAC-
ROD2 locus was an association specific to risk of TO in GD.
Four additional highly ranked SNPs at the MACROD2 gene
locus with P < 104 extracted from the discovery pooled
GWAS data also were assessed for their linkage disequilibrium
to rs6110809 in the Caucasian HapMap population. They are
rs978767 (P ¼ 1.8 3 104), rs175805 (P ¼ 3.05 3 107),
rs6135575 (P ¼ 4.32 3 104), and rs761684 (P ¼ 3.2 3 104).
Two SNPs were highly correlated with rs6110809 (rs6135575
and rs761684) and two SNPs showed more moderate linkage
disequilibrium with rs6110809 (rs978767 and rs175805;
Figure). This suggests the top ranking MACROD2 SNPs may
represent two separate loci within MACROD2 associated with
TO, although further genotyping and analysis are required to
confirm this.
DISCUSSION
This GWAS discovered a positive association of SNP on
chromosome 20 within the MACROD2 gene with TO with
replication in an independent cohort. The genetic variant
appeared specific to the risk for TO in patients with GD and
not for the risk of GD itself, potentially implicating MACROD2
as a new genetic susceptibility locus for TO. Multiple genetic
loci on chromosome 10, 7, 5, and 3 trended towards positive
association with TO but the associations dropped out of
significance in subsequent individual genotyping.
To our knowledge, this is the first study to characterize the
genetic risk factors for TO using a GWAS approach, where
associated loci were discovered a priori and confirmation of
these findings in additional independent cohorts was per-
formed. While none of the SNPs reached genome-wide
significance, there was evidence of association of MACROD2
with TO first reported by this study. The evidence of
association with MACROD2 stays true overall with adjustment
for potential confounders age, duration of GD, sex, and
smoking in the combined dataset, bearing in mind that the
smoking data are absent in 10.9% of the replication cohorts,
and 6.6% in the combined cohorts dataset, which might affect
the final estimation of OR and its significance level when
smoking was taken into consideration. Hence, we have
presented the data in this study for confounder adjustments
with and without smoking and found P values slightly







Case Control P Value Case Control P Value Case Control P Value
N 265 147 231 142 88 78
Mean age, y (SD) 46.7 (13.8) 42.7 (15.2) 0.01 46.4 (13.5) 42.4 (16.2) 0.01 46.5 (14.0) 40.1 (15.5) 0.01
GD Duration, y (SD) 10.91 (9.66) 5.42 (6.83) <0.001 8.67 (8.83) 5.46 (6.04) <0.001 8.32 (9.47) 5.56 (7.71) 0.05
Sex
Male (%) 47 (20.4) 24 (16.3) 0.717 47 (20.4) 36 (25.4) 0.262 13 (15.1) 13 (16.7) 0.79
Female (%) 218 (79.7) 123 (83.7) 184 (79.7) 106 (74.7) 73 (84.9) 65 (83.3)
Smoking status
Smoker (%) 66 (25.2) 25 (17.1) <0.001 69 (29.9) 25 (17.6) <0.001 15 (21.7) 6 (15.8) 0.02
Ex-smoker (%) 110 (42) 42 (28.8) 79 (34.2) 34 (23.9) 9 (13.1) 14 (36.8)
Never smoked (%) 86 (32.8) 79 (54.1) 83 (35.9) 83 (58.5) 45 (65.2) 18 (47.4)
*3 missing *1 missing *19 missing *40 missing
TABLE 2. Demographics of Overall Cohort With GD, TO Compared to Normal Healthy Controls
TO Compared to Normal Controls GD Compared to Normal Controls
TO Cases Normal Controls P Value Graves’ Cases Normal Controls P Value
N 584 282 951 282
Mean age, y (SD) 46.5 (13.7) 75.9 (8.18) <0.001 44.8 (14.7) 75.9 (8.18) <0.001
Sex
Male (%) 107 (18.38) 116 (42.96) <0.001 180 (18.97) 116 (42.96) <0.001
Female (%) 475 (81.62) 154 (57.04) 769 (81.03) 154 (57.04)
*2 missing *12 missing *2 missing *12 missing
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increased after smoking adjustment. A further limitation of this
study is the use of pooled DNA, which, although highly
economical, reduces the ability to correct for confounders in
the GWAS stage, or to assess population substructure, which
may lead to false-positive findings. While we and others find
limited evidence for genes with major effects affecting risk for
TO,18,39 the number of cases studied in this study still is
relatively small, limiting the power and certainty of the
association found. Much larger samples will be required to
confirm our findings and to prove genetic associations in TO.
Nevertheless, the identification of genetic variants, even of
modest effects, will improve our understanding of pathogen-
esis of TO and identify pathways for therapeutic consider-
ations. In the context of these provisions, we will discuss the
results of interest from this study that are potentially relevant
to the genetic risk of TO.
The OR for rs6110809 A allele in predicting risk for TO
ranges between 2.77 for the pooled discovery cohort and 1.42
in the replication cohorts, with an OR of 1.81 for the extended
cohort when all cohorts were combined after adjusting for age
at disease onset, duration of GD, and sex. The OR is notably
smaller in the replication cohorts, which is consistent with
‘‘the winner’s curse’’ where locus-specific size estimate bias
upwards in GWAS.40 Hence, if the association of rs6110809 is
true, the estimated conferred risk is more realistic from the
replication samples, where the estimated effect size also is
more in line with unbiased estimates of ORs discovered by
GWAS studies of approximately 1.1 to 1.3.41
The MACROD2 gene encodes a protein with a highly
conserved macrodomain binding module in the N-terminal
domain that interacts with mono-ADP-ribosylated pro-
teins.42,43 There are no existing data as to whether MACROD2
is expressed in the orbital adipocytes or myofibroblasts, and
further studies are required to examine this. However,
MACROD2 is expressed strongly in the brain, and is
moderately to strongly expressed in cuboidal epithelium of
the lens and the inner nuclear layer of the retina.42 The
association of MACROD2 with eye diseases has not been
previously reported to our knowledge, but genetic variants in
MACROD2 have been reported to be associated with
neuropsychiatric disorders. De novo deletion of exon 5
within MACROD2 was identified in Kabuki syndrome, where
the index case suffered from mental retardation and had
ophthalmic features including ptosis, hypermetropic astigma-
tism, alternating strabismus, and blue sclera.42 MACROD2
allelic variants and common copy number gain has been
linked to several diseases.41,44–46 Recent GWAS identified
SNPs within MACROD2 as a risk variant in autism spectrum
disorder,41 and possibly a protective factor for MRI-defined
brain infarcts.44 A candidate gene study investigating autistic-
like traits also reported an association between rs4141463
SNP in intron 5 of MACROD2.45 Overexpression of MACROD2
mediates estrogen-independent growth and tamoxifen resis-
tance in breast cancer, suggesting the expressed gene confers
advantage to cellular survival.46
The MACROD2 protein binds to mono-ribosylated proteins
and its catalytic domain functions as O-acetyl-ADP-ribose
deacetylases and hydrolases, which reverses mono-ADP
ribosylation,43,47 thus underlying the key role of MACROD2
as an eraser of mono-ADP-ribosylation.48 The function of
macrodomain molecules in general is tightly linked to ADP-
ribosylation, which modulate functions of protein by posttran-
scriptional modification. The addition of ADP-ribose to
proteins affects diverse cellular processes including DNA
repair, chromatin remodeling, gene transcription, lipid metab-
olism, and apoptotic processes.48–50 To understand the role of
MACROD2 in disease, we must understand the function of
intracellular ADP-ribosyltransferase Cholera toxin-like (ARTD),
which inserts ADP-ribose monomers to protein that MACROD2
erases. ARTD10 regulates cell signaling, represses nuclear
factor-jb by mono-ribosylation of NF-jb essential modulator
(NEMO), where NF-jb signaling pathway promotes inflamma-
tion, innate immune response, cellular proliferation, and cell
survival.48,50–53
Overexpression of ARTD10 promotes apoptosis in HeLa
cells whereas ARTD10 knockdown increases cell survival upon
DNA damage caused by DNA damaging agents.54 ARTD10 is
inducible by inflammatory and immunogenic stimuli, hence
suggesting its role in innate immunity.48 ARTD10 also inhibits
glycogen synthase kinase 3b (GSK3b), a key enzyme that
modulates WNT signaling via b-catenin phosphorylation,
which regulate apoptosis, immunity, and development of
neurodegenerative diseases.43,48,55,56 Hence, inhibition of
GSK3b and NF-jb signaling by ARTD10 may explain enhanced
apoptosis and MACROD2, on the other hand, counteracts the
actions of ARTD10.
The role of MACROD2 in modulating DNA repair is yet
unknown, but it is recruited to poly-ADP-ribose synthesized by
ARTD1 in response to DNA damage.50 MACROD2 removes the
most proximal ADP ribose linked to the target amino acid after
partial breakdown of poly-ADP-ribosylation by poly-ADPr-
glycohydrolase to fully reverse ARTD1 regulatory modifica-
tion.57 This functional link of MACROD2 to ARTD1 becomes
more noteworthy in light of the findings that carriers of G allele
of ARTD1 G1672A polymorphism are at risk of GD and a
positive association of ARTD1 C410T polymorphism with TO
confers an increased risk of TO by 1.7 times.58
MACROD2 and ARTD10 regulation of apoptosis and NF-jb
signaling may be relevant to the mechanism of immune-
mediated orbital inflammation in TO. Gene set enrichment
analysis of molecular signatures of TO revealed dysregulation
of epigenetic signatures, T cell activation, Th1 differentiation,
FIGURE. Haploview linkage disequilibrium plot for 5 highly ranked
SNPs within MACROD2 in HapMap CEU population data.
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defensin pathway, apoptosis among a few in active TO.59
Dysregulation of WNT signaling also was evident in TO from
microarray studies.60,61 Orbital inflammation in TO is
mediated by communication of orbital fibroblast and fibro-
cytes with immune cells via CD40-CD40 ligand. This is
inducible by IFN-c, evidenced by nuclear translocation of NF-
jb and increase secretion of pro-inflammatory cytokine IL-6
and IL-8 upon triggering of CD40 bearing orbital fibroblast by
CD40 ligand.62,63 CD40 ligand significantly increases inter-
cellular adhesion molecule-1 (ICAM-1) protein in a dose- and
time-dependent manner, where ICAM-1 has a role in initiating
and sustaining inflammatory immune response.64 The signal-
ing pathways of increased ICAM-1 involve mitogen activated
protein kinases and NF-jb; CD40 ligand at 100 ng/mL induced
a moderate activation of NF-jb, which increases in a time-
dependent manner.64 In addition, polymorphisms of del/ins
of NFjb1 gene may be related to the development of TO,
further supporting the role of NF-jb in TO pathogenesis.58
Overexpression of MACROD2 is expected to enhance NF-jb
signaling and increase cell survival, cell proliferation,
inflammation and immune response, mechanisms all relevant
to the pathogenesis of TO. The functional study of MACROD2
is beyond the scope of this study; this study provided grounds
for further candidate gene study and future functional studies
looking at expression levels of MACROD2 in orbital fibro-
blasts culture, and its effects on IL-6, IL-8, ICAM-1, NF-jb
expression levels in vitro.
In conclusion, this exploratory GWAS study of TO suggests
that in patients with GD, a common variant at the MACROD2
locus increases susceptibility to TO. This novel finding should
prompt further replication studies to confirm its role in the
pathogenesis of TO.
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